The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.
If approved under the accelerated pathway, Novartis is likely to compete with Alexion’s C5-targeting therapy Soliris (eculizumab), which became the first treatment for all patients with PNH and atypical
This includes the company’s complement component 5 (C5) inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab), which are already available in the US and EU. ... AZ is also projecting that the acquisition will deliver double-digit average annual
Roche’s neuromyelitis optica spectrum disorder (NMOSD) drug Enspryng has scored US Food and Drug Administration (FDA) approval, setting up a market clash with Alexion’s Soliris. ... The first approved treatment in the US for NMOSD is Alexion’s
Shares shot up more than 50% in wake of announcement. Apellis has new data showing that its pegcetacoplan drug outperformed Alexion’s market leading Soliris in rare disease paroxysmal nocturnal haemoglobinuria ... with C5 inhibitor Soliris and
Alexion also received European Commission approval for the extended use of Soliris in the same indication in August. ... However, both Roche and Alexion could face competition from biosimilars, as Amgen recently filed a patent infringement action
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...